- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Outlook Therapeutics Inc (OTLK)
Outlook Therapeutics Inc stock price live, this page displays NASDAQ OTLK stock exchange data. View the OTLK premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Outlook Therapeutics Inc real time stock price chart below.
What Is the Outlook Therapeutics Inc Stock Price Today?
The Outlook Therapeutics Inc stock price today is 0.593.
What Is the Stock Symbol for Outlook Therapeutics Inc?
The stock symbol for Outlook Therapeutics Inc is "OTLK."
What Stock Exchange Does Outlook Therapeutics Inc Trade On?
Outlook Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Outlook Therapeutics Inc a Good Stock to Buy?
Determining whether Outlook Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OTLK quote. (ISIN: US69012T3059)
What Is the Outlook Therapeutics Inc Stock Price Today?
The Outlook Therapeutics Inc stock price today is 0.593.
What Is the Stock Symbol for Outlook Therapeutics Inc?
The stock symbol for Outlook Therapeutics Inc is "OTLK."
What Stock Exchange Does Outlook Therapeutics Inc Trade On?
Outlook Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Outlook Therapeutics Inc a Good Stock to Buy?
Determining whether Outlook Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OTLK quote. (ISIN: US69012T3059)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.572
0.607
52 wk Range
0.161
2.538
OTLK is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.5720.607
52 wk Range
0.1612.538
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
OTLK Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
5.025
Upside
+747.39%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.025
(+747.39% Upside)
Outlook Therapeutics Inc Earnings Call Summary for Q3/2026
- Q3 adjusted net loss narrowed to $10.9M ($0.09/share) from $15.8M ($0.44/share) YoY; shares fell 5.5% on costly launch plans ahead.
- LYTENAVA received FDA approval; company projects $50M-$75M revenue in first 12 months post-U.S. launch, targeting $500M+ peak sales by 2030.
- Raised $51.1M net through public offering; ended quarter with $11.2M cash as SG&A expenses expected to double by end of 2026.
- European unit sales rose 46% sequentially; permanent J-code expected April 2027, viewed as key inflection point for adoption growth.
- Plans to hire ~50 commercial/reimbursement staff; faces competition from biosimilars and off-label repackaged bevacizumab in crowded market.
Last Updated: 2026-08-14, 09:26 a/m
Read Full TranscriptEarnings
Latest Release
Aug 14, 2026
EPS / Forecast
-0.15 / -0.26
Revenue / Forecast
9K / --
Compare OTLK to Peers and Sector
Metrics to compare | OTLK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOTLKPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.4x | −0.9x | −0.4x | |
PEG Ratio | −0.05 | −0.04 | 0.00 | |
Price/Book | −13.9x | 2.5x | 2.6x | |
Price / LTM Sales | −124.1x | 52.4x | 3.0x | |
Upside (Analyst Target) | - | 192.0% | 58.2% | |
Fair Value Upside | Unlock | 20.2% | 7.7% | Unlock |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Outlook Therapeutics (OTLK) Stock Price Today?
The Outlook Therapeutics stock price today is 0.593 USD.
What Stock Exchange Does Outlook Therapeutics Trade On?
Outlook Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Outlook Therapeutics?
The stock symbol for Outlook Therapeutics is "OTLK."
What Is the Outlook Therapeutics Market Cap?
As of today, Outlook Therapeutics market cap is 144.360M USD.
What Is Outlook Therapeutics's Earnings Per Share (TTM)?
The Outlook Therapeutics EPS (TTM) is -0.748.
From a Technical Analysis Perspective, Is OTLK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Outlook Therapeutics Stock Split?
Outlook Therapeutics has split 2 times.
How Many Employees Does Outlook Therapeutics Have?
Outlook Therapeutics has 17 employees.
What is the current trading status of Outlook Therapeutics (OTLK)?
As of Oct 04, 2026, Outlook Therapeutics (OTLK) is trading at a price of 0.593 USD, with a previous close of 0.593 USD. The stock has fluctuated within a day range of 0.572 USD to 0.607 USD, while its 52-week range spans from 0.161 USD to 2.538 USD.
What Is Outlook Therapeutics (OTLK) Price Target According to Analysts?
The average 12-month price target for Outlook Therapeutics is 5.025 USD, with a high estimate of 10.5 USD and a low estimate of 1.6 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +747.39% Upside potential.
What Is the OTLK Premarket Price?
OTLK's last pre-market stock price is 0.594 USD. The pre-market share volume is 75,770.000, and the stock has decreased by 0.019, or 3.300%.
What Is the OTLK After Hours Price?
OTLK's last after hours stock price is 0.598 USD, the stock has decreased by 0.005, or 0.830%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.